SLC5A2 and pulmonary hypertension: The present study validated a high-fat diet-induced rat model of early HFpEF developing pulmonary hypertension, which may offer a new avenue for testing potential mechanisms and therapeutic interventions, such treatment with the promising sodium-glucose co-transporter 2 (SGLT2) inhibitors that have shown recently beneficial effects in patients with HFpEF (64).